Healthcare giant Abbott (NYSE:ABT) announced this week that it won CE Mark approval in the European Union for its FreeStyle Optium Neo, a daily-use blood glucose and ketone monitoring system for diabetes management.
The FreeStyle Optium Neo system, the latest in Abbott’s FreeStyle line, features analytics that highlight glucose trends and log insulin, and was developed with new ease-of-use measures and a smaller design profile, the company said.
Abbott plans to release the device on European markets "in the coming weeks," according to a press release.
Abbott has been busy lately, with 2 buyouts last month and a rumored buyout of Johnson & Johnson’s (NYSE:JNJ) Ortho Clinical Diagnostics blood testing business. Abbott late last month closed the $310 million buyout of IDEV Technologies and its self-expanding stent, just days after the company closed its buyout of OptiMedica, a deal worth up to $400 million.